BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 16505275)

  • 1. High predictive value of epidermal growth factor receptor phosphorylation but not of EGFRvIII mutation in resected stage I non-small cell lung cancer (NSCLC).
    Sonnweber B; Dlaska M; Skvortsov S; Dirnhofer S; Schmid T; Hilbe W
    J Clin Pathol; 2006 Mar; 59(3):255-9. PubMed ID: 16505275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor (EGFR) mutation and p-EGFR expression in resected non-small cell lung cancer.
    McMillen E; Ye F; Li G; Wu Y; Yin G; Liu W
    Exp Lung Res; 2010 Nov; 36(9):531-7. PubMed ID: 20939760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer.
    Haura EB; Zheng Z; Song L; Cantor A; Bepler G
    Clin Cancer Res; 2005 Dec; 11(23):8288-94. PubMed ID: 16322287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of epidermal growth factor receptor (EGFR) gene mutations on the expression of EGFR, phosphoryl-Akt, and phosphoryl-MAPK, and on the prognosis of patients with non-small cell lung cancer.
    Sonobe M; Nakagawa M; Takenaka K; Katakura H; Adachi M; Yanagihara K; Otake Y; Wada H; Tanaka F
    J Surg Oncol; 2007 Jan; 95(1):63-9. PubMed ID: 17192868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclooxygenase-2 protein levels are independent of epidermal growth factor receptor expression or activation in operable non-small cell lung cancer.
    Richardson CM; Richardson D; Swinson DE; Swain WA; Cox G; O'Byrne KJ
    Lung Cancer; 2005 Apr; 48(1):47-57. PubMed ID: 15777970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic and diagnostic relevance of hnRNP A2/B1, hnRNP B1 and S100 A2 in non-small cell lung cancer.
    Zech VF; Dlaska M; Tzankov A; Hilbe W
    Cancer Detect Prev; 2006; 30(5):395-402. PubMed ID: 17067748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coexpression, prognostic significance and predictive value of EGFR, EGFRvIII and phosphorylated EGFR in colorectal cancer.
    Cunningham MP; Essapen S; Thomas H; Green M; Lovell DP; Topham C; Marks C; Modjtahedi H
    Int J Oncol; 2005 Aug; 27(2):317-25. PubMed ID: 16010411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression.
    Rusch V; Klimstra D; Venkatraman E; Pisters PW; Langenfeld J; Dmitrovsky E
    Clin Cancer Res; 1997 Apr; 3(4):515-22. PubMed ID: 9815714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive analysis of EGFR signaling pathways in Japanese patients with non-small cell lung cancer.
    Hosokawa S; Toyooka S; Fujiwara Y; Tokumo M; Soh J; Takigawa N; Hotta K; Yoshino T; Date H; Tanimoto M; Kiura K
    Lung Cancer; 2009 Oct; 66(1):107-13. PubMed ID: 19185949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer.
    Schneider PM; Praeuer HW; Stoeltzing O; Boehm J; Manning J; Metzger R; Fink U; Wegerer S; Hoelscher AH; Roth JA
    Br J Cancer; 2000 Aug; 83(4):473-9. PubMed ID: 10945494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor gene amplification in surgical resected Japanese lung cancer.
    Sasaki H; Shimizu S; Okuda K; Kawano O; Yukiue H; Yano M; Fujii Y
    Lung Cancer; 2009 Jun; 64(3):295-300. PubMed ID: 19058870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Silver-enhanced in situ hybridization for determination of EGFR copy number alterations in non-small cell lung cancer.
    Wulf MA; Bode B; Zimmermann D; Rufibach K; Weder W; Moch H; Soltermann A; Tischler V
    Am J Surg Pathol; 2012 Dec; 36(12):1801-8. PubMed ID: 23154768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The survival outcomes of patients with resected non-small cell lung cancer differ according to EGFR mutations and the P21 expression.
    Na II; Rho JK; Choi YJ; Kim CH; Park JH; Koh JS; Ryoo BY; Yang SH; Lee JC
    Lung Cancer; 2007 Jul; 57(1):96-102. PubMed ID: 17337084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor ligand/receptor loop and downstream signaling activation pattern in completely resected nonsmall cell lung cancer.
    Volante M; Saviozzi S; Rapa I; Ceppi P; Cappia S; Calogero R; Novello S; Borasio P; Papotti M; Scagliotti GV
    Cancer; 2007 Sep; 110(6):1321-8. PubMed ID: 17647268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: a chromogenic in situ hybridization study of 182 patients.
    Chang JW; Liu HP; Hsieh MH; Fang YF; Hsieh MS; Hsieh JJ; Chiu YT; Tsai HY; Chen YH; Chen YT; Hsu HY; Chen YT; Tsai SF; Chen YR; Hsi BL; Huang SF
    Lung Cancer; 2008 Sep; 61(3):328-39. PubMed ID: 18304690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.
    Bell DW; Lynch TJ; Haserlat SM; Harris PL; Okimoto RA; Brannigan BW; Sgroi DC; Muir B; Riemenschneider MJ; Iacona RB; Krebs AD; Johnson DH; Giaccone G; Herbst RS; Manegold C; Fukuoka M; Kris MG; Baselga J; Ochs JS; Haber DA
    J Clin Oncol; 2005 Nov; 23(31):8081-92. PubMed ID: 16204011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer.
    Chou TY; Chiu CH; Li LH; Hsiao CY; Tzen CY; Chang KT; Chen YM; Perng RP; Tsai SF; Tsai CM
    Clin Cancer Res; 2005 May; 11(10):3750-7. PubMed ID: 15897572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective study of the accuracy of EGFR mutational analysis by high-resolution melting analysis in small samples obtained from patients with non-small cell lung cancer.
    Fukui T; Ohe Y; Tsuta K; Furuta K; Sakamoto H; Takano T; Nokihara H; Yamamoto N; Sekine I; Kunitoh H; Asamura H; Tsuchida T; Kaneko M; Kusumoto M; Yamamoto S; Yoshida T; Tamura T
    Clin Cancer Res; 2008 Aug; 14(15):4751-7. PubMed ID: 18676744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for activating EGFR mutations in surgically resected nonsmall cell lung cancer.
    Sriram KB; Tan ME; Savarimuthu SM; Wright CM; Relan V; Stockwell RE; Clarke BE; Duhig EE; Yang IA; Bowman RV; Fong KM
    Eur Respir J; 2011 Oct; 38(4):903-10. PubMed ID: 21349912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas. An immunohistochemical and fluorescence in situ hybridization study.
    Suzuki S; Dobashi Y; Sakurai H; Nishikawa K; Hanawa M; Ooi A
    Cancer; 2005 Mar; 103(6):1265-73. PubMed ID: 15712203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.